- Eleven presentations of HUMIRA® (adalimumab) and pipeline data showcase breadth and depth of robust gastroenterology portfolio
- First presentation of efficacy and safety results from the Phase 2b U-ACHIEVE study evaluating upadacitinib in ulcerative colitis to be presented during an oral presentation[1]
- Oral presentation of longer-term Phase 2 open-label extension study evaluates risankizumab in moderate to severe Crohn's disease[2]
- Additional analysis from the CALM study shows the impact of dose optimization based on a tight control approach with HUMIRA[3]
PR Newswire
NORTH CHICAGO, Ill., Oct. 16, 2018